Micah R Whitson1, Edwin Mo2, Tasnima Nabi3, Lauren Healy3, Seth Koenig4, Mangala Narasimhan4, Paul H Mayo4. 1. Department of Emergency/Internal/Critical Care Medicine, North Shore-LIJ Health System, New Hyde Park, NY. Electronic address: micahwhitson64@gmail.com. 2. Department of Emergency/Internal/Critical Care Medicine, North Shore-LIJ Health System, New Hyde Park, NY. 3. Department of Pharmacy, North Shore-LIJ Health System, New Hyde Park, NY. 4. Department of Pulmonary and Critical Care Medicine, North Shore-LIJ Health System, New Hyde Park, NY.
Abstract
BACKGROUND: We describe the feasibility, utility, and safety of oral midodrine to replace IV vasopressors during recovery from septic shock. METHODS: This was a retrospective study performed in a medical ICU. All study subjects had a diagnosis of septic shock requiring at least 24 hours of IV vasopressors and demonstrated clinical stability with stable or decreasing doses of IV vasopressors. The two groups compared were those who received IV vasopressors only and those who received IV vasopressors with adjunctive midodrine. RESULTS: Of the 275 study patients, 140 received an IV vasopressor only and 135 received midodrine in addition to an IV vasopressor. There was no difference between the groups' demographics (age, sex, Acute Physiology and Chronic Health Evaluation 4 score). Mean IV vasopressor duration was 3.8 days in the IV vasopressor only group and 2.9 days in the IV vasopressor with midodrine group (P < .001). An IV vasopressor was reinstituted after discontinuation in 21 of 140 (15%) patients in the IV vasopressor only group and in 7 of 135 (5.2%) patients in the IV vasopressor with midodrine group (P = .007). ICU length of stay was 9.4 days in the IV vasopressor only group and 7.5 days in the IV vasopressor with midodrine group (P = .017). There were no complications associated with midodrine use except transient bradycardia in one patient, which resolved upon discontinuation of midodrine. CONCLUSIONS: Midodrine may reduce the duration of IV vasopressors during recovery phase from septic shock and may be associated with a reduction in length of stay in the ICU.
BACKGROUND: We describe the feasibility, utility, and safety of oral midodrine to replace IV vasopressors during recovery from septic shock. METHODS: This was a retrospective study performed in a medical ICU. All study subjects had a diagnosis of septic shock requiring at least 24 hours of IV vasopressors and demonstrated clinical stability with stable or decreasing doses of IV vasopressors. The two groups compared were those who received IV vasopressors only and those who received IV vasopressors with adjunctive midodrine. RESULTS: Of the 275 study patients, 140 received an IV vasopressor only and 135 received midodrine in addition to an IV vasopressor. There was no difference between the groups' demographics (age, sex, Acute Physiology and Chronic Health Evaluation 4 score). Mean IV vasopressor duration was 3.8 days in the IV vasopressor only group and 2.9 days in the IV vasopressor with midodrine group (P < .001). An IV vasopressor was reinstituted after discontinuation in 21 of 140 (15%) patients in the IV vasopressor only group and in 7 of 135 (5.2%) patients in the IV vasopressor with midodrine group (P = .007). ICU length of stay was 9.4 days in the IV vasopressor only group and 7.5 days in the IV vasopressor with midodrine group (P = .017). There were no complications associated with midodrine use except transient bradycardia in one patient, which resolved upon discontinuation of midodrine. CONCLUSIONS:Midodrine may reduce the duration of IV vasopressors during recovery phase from septic shock and may be associated with a reduction in length of stay in the ICU.
Authors: James M Walter; Jacqueline M Kruser; Paul A Reyfman; Peter H S Sporn Journal: Am J Respir Crit Care Med Date: 2017-03-01 Impact factor: 21.405
Authors: Elizabeth M Viglianti; Sean M Bagshaw; Rinaldo Bellomo; Joanne McPeake; Daniel J Molling; Xiao Qing Wang; Sarah Seelye; Theodore J Iwashyna Journal: Chest Date: 2020-04-09 Impact factor: 9.410
Authors: Dina Hussein El Adly; Naglaa Samir Bazan; Radwa Maher El Borolossy; Islam Fawzy Anan; Mohamed Amin Fakher; Lamia Mohamed El Wakeel Journal: Ir J Med Sci Date: 2022-01-03 Impact factor: 1.568
Authors: Peter Santer; Matthew H Anstey; Maria D Patrocínio; Bradley Wibrow; Bijan Teja; Denys Shay; Shahzad Shaefi; Charles S Parsons; Timothy T Houle; Matthias Eikermann Journal: Intensive Care Med Date: 2020-09-03 Impact factor: 17.440
Authors: Ahmad Al-Abdouh; Sadam Haddadin; Atul Matta; Ahmad Jabri; Mahmoud Barbarawi; Waiel Abusnina; Qais Radideh; Mohammed Mhanna; Dante A Suffredini; Erin D Michos Journal: Crit Care Res Pract Date: 2021-05-15